Search
Now showing items 1-5 of 5
“INCORPORACIÓN DEL BIOMARCADOR ALFA-FETOPROTEÍNA COMO CRITERIO DE SELECCIÓN PARA TRASPLANTE HEPÁTICO POR HEPATOCARCINOMA”.
(2020)
El trasplante hepático es una de las terapéuticas curativas en pacientes con
hepatocarcinoma (HCC) o carcinoma hepatocelular. Sin embargo, la
recurrencia post trasplante hepático es un evento temible, con pobre sobrevida ...
LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study
(Elsevier, 2020-11)
Abstract
Introduction and objectives: The liver imaging reporting data system (LI-RADS) for hepatocellular carcinoma (HCC) was proposed to standardize and enhance consensus of reporting. However, clinical utility of LI-RADS ...
Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma
(Elsevier, 2020-10)
Abstract
The A.A.E.E.H has developed this guideline for the best care of patients with hepatocellular carcinoma (HCC) from Argentina. It was done from May 2018 to March 2020. Specific clinical research questions were ...
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
(2020-06)
Abstract
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and treatment strategies to improve the prognosis ...
Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.
(Elsevier, 2020-10)
Abstract
Background & aims: Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new ...